Search

Your search keyword '"Feasi, M"' showing total 4 results
Start Over Author "Feasi, M" Topic hepatitis b
4 results on '"Feasi, M"'

1. Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status.

Author

Nicolini LA, Taramasso L, Schiavetti I, Giannini EG, Beltrame A, Feasi M, Cassola G, Grasso A, Bartolacci V, Sticchi L, Picciotto A, and Viscoli C

Subjects
Adult, Carrier State, Coinfection, Female, HIV isolation & purification, HIV Infections blood, HIV Infections virology, Hepatitis B blood, Hepatitis B virology, Hepatitis B virus isolation & purification, Hepatitis D blood, Hepatitis D virology, Hepatitis Delta Virus isolation & purification, Humans, Incidence, Italy epidemiology, Male, Middle Aged, Retrospective Studies, Risk Factors, Substance Abuse, Intravenous blood, Substance Abuse, Intravenous virology, HIV Infections epidemiology, Hepatitis B epidemiology, Hepatitis B Surface Antigens blood, Hepatitis D epidemiology, Substance Abuse, Intravenous epidemiology
Abstract

Background: The epidemiology of HBV-associated hepatitis has changed in recent years, especially after the introduction of anti-HBV vaccination, with a consequent decrease in the incidence of HDV-associated hepatitis. However, HDV remains of concern in non-vaccinated people and in immigrants. The aim of this retrospective survey has been to assess prevalence and clinical characteristics of HDV infection in Liguria, a region in Northern Italy, in both HIV-positive and negative patients., Methods: During the year 2010, 641 patients chronically infected with HBV entered an observational study of HBV infection conducted in eight tertiary care centres belonging to the 'Ligurian HBV Study Group'., Results: Of 641 patients, 454 (70.8%) were evaluated for HDV serology and 26 (5.7%) were found positive. Among them, 16 were also HIV-positive and 10 were not. Of the 428 HDV-negative patients, only 313 were tested for HIV and 33 (10.5%) were positive. At the time point of study entry there was no age difference between HIV-positive or negative patients, but HIV-positive patients were 10 years younger than HIV-negative (mean age 34.25 ±6.16 versus 41.50 ±8.89 years; P=0.021) at the time point of their first visit in each centre and they were also more frequently intravenous drug users (P=0.009). Despite a similar rate of cirrhosis in the two groups, no HIV-positive patient received an HDV-active therapy (that is, interferon), versus 4 of 10 HIV-negative patients (P=0.014)., Conclusions: HDV infection is still a problem in patients not covered by HBV vaccination. Both HDV and HIV testing were frequently overlooked in our setting.

Published
2015
Full Text
View/download PDF

2. Hepatitis B reactivation prophylaxis in immune-suppressed patients.

Author

Torresin A, Feasi M, and Cassola G

Subjects
Antiviral Agents therapeutic use, DNA, Viral drug effects, Hepatitis B drug therapy, Hepatitis B virus drug effects, Humans, Immunocompromised Host drug effects, Virus Activation drug effects, Hepatitis B prevention & control, Hepatitis B virus physiology, Immunocompromised Host immunology, Lamivudine therapeutic use, Virus Activation physiology
Published
2008
Full Text
View/download PDF

4. Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden

Author

Torre, F, Basso, Monica, Giannini, Eg, Feasi, M, Boni, S, Grasso, A, De Leo, P, Dodi, F, Marazzi, Mg, Azzola, E, Bartolacci, V, Percario, G, Beltrame, A, Borro, P, Picciotto, A, and Ligurian HBV Study Group

Subjects
Adult, Liver Cirrhosis, Male, Carcinoma, Hepatocellular, Adolescent, HIV Infections, Comorbidity, medicine.disease_cause, Cohort Studies, Young Adult, Liver disease, Hepatitis B, Chronic, Orthohepadnavirus, Risk Factors, Virology, Prevalence, medicine, Humans, Hepatitis B e Antigens, Child, Aged, Aged, 80 and over, Hepatitis B virus, Hepatitis, Hepatitis B Surface Antigens, biology, business.industry, Hepatitis C, Middle Aged, Hepatitis B, medicine.disease, biology.organism_classification, Hepatitis D, Cross-Sectional Studies, Infectious Diseases, Italy, Child, Preschool, Female, Hepatitis D virus, business
Abstract

The aim of this study was to determine the prevalence of hepatitis B virus (HBV) infection in an Italian region, Liguria (1,572,000 inhabitants), by means of a network of 12 referral centers for liver diseases. All patients with HBV surface antigen followed throughout 2006 were included. Personal data, infectious status with risk factors, other non-infectious risk factors for liver disease, clinical status, and treatment were the questionnaire. Four hundred forty-five patients (71% male) were evaluated. Their median age was 48 years (range 5–84), and 83.4% were of Italian origin. Community-acquired infection was the principal mode of HBV transmission (82.5%), followed by previous intravenous drug use (9.4%), perinatal transmission (6.3%), and transfusion-associated transmission (1.8%). Hepatitis B e-antigen was present in 20.4% of the patients, while co-infections with hepatitis D virus and/or hepatitis C virus and/or human immunodeficiency virus (HIV) were observed in 18.7% of the patients. Chronic active hepatitis was present in 62.5% of the patients, cirrhosis in 13.5%, hepatocellular carcinoma in 2.2%, and 21.8% of the patients were inactive carriers of HBV. In all, 42.5% of the patients were treated with interferon or lamivudine and/or adefovir-dipivoxil. Forty-nine patients were co-infected with HIV (86% on highly active antiviral therapy). Nevertheless, this study identified only 2.2% of the expected patients with HBV. Hence, it has to be reasoned that few potential infectious or treatable patients are referred to liver disease centers. HBV infection is still an underestimated health problem, and few potential infectious or treatable patients are referred to tertiary centers. J. Med. Virol. 81:1882–1886, 2009. © 2009 Wiley-Liss, Inc.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results